PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.

Zschaeck S; Lohaus F; Beck M; Habl G; Kroeze S; Zamboglou C; Koerber SA; Debus J; Hölscher T; Wust P; Ganswindt U; Baur ADJ; Zöphel K; Cihoric N; Guckenberger M; Combs SE; Grosu AL; Ghadjar P; Belka C

doi:10.1186/s13014-018-1047-5

Back

Journal article

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.

Zschaeck S Department of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany. Sebastian.Zschaeck@charite.de.
Lohaus F Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Beck M Department of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.
Habl G Department of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany.
Kroeze S Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Zamboglou C Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Dresden, Germany.
Koerber SA Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Debus J Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Hölscher T Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Wust P Department of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.
Ganswindt U Department of Therapeutic Radiology and Oncology, Innsbruck Medical University, Innsbruck, Austria.
Baur ADJ Department of of Radiology, Universitätsmedizin Berlin, Berlin, Germany.
Zöphel K Nuclear Medicine Department, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Cihoric N Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, München, Switzerland.
Guckenberger M Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Combs SE Department of Radiation Oncology, Technical University of Munich (TUM), Munich, Germany.
Grosu AL Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Dresden, Germany.
Ghadjar P Department of Radiation Oncology, Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.
Belka C Department of Radiation Oncology, Ludwig-Maximilians-University, Munich, Germany.

2018-05-13

Published in:

Radiation oncology (London, England). - 2018

Image guided treatment planning

Practice Patterns, Physicians'

English 68Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography (PET) is an increasingly used imaging modality in prostate cancer, especially in cases of tumor recurrence after curative intended therapy. Owed to the novelty of the PSMA-targeting tracers, clinical evidence on the value of PSMA-PET is moderate but rapidly increasing. State of the art imaging is pivotal for radiotherapy treatment planning as it may affect dose prescription, target delineation and use of concomitant therapy.This review summarizes the evidence on PSMA-PET imaging from a radiation oncologist's point of view. Additionally a short survey containing twelve examples of patients and 6 additional questions was performed in seven mayor academic centers with experience in PSMA ligand imaging and the findings are reported here.

Language